Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 11c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of $0.02, $0.11 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $4.11 million.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• Sphere Entertainment (SPHR) Reiterated at Market Outperform by Citizens: Global Expansion Apace
• GE Vernova T&D India (GVTD:IN) PT Raised to INR5,300 at Emkay Global
• Citi raises Atlassian price target to $225, maintains Buy rating